Under Food and Drug Administration investigational device exemption , the Prospective Randomized On-X Anticoagulation Clinical Trial ( PROACT ) has been testing the safety of less aggressive anticoagulation than recommended by the American College of Cardiology/American Heart Association guidelines after implantation of an approved bileaflet mechanical valve .